Using a genetic test to guide blood thinner prescriptions after a stroke
Implementation of Onsite Rapid CYP2C19 Assay for Genotype Guided Dual Antiplatelet Therapy After Acute Ischemic Stroke
This study is testing whether a quick genetic test can help doctors choose the right blood thinners for patients who have had a stroke or mini-stroke.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 350 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Virginia Academic / other |
| Locations | 1 site (Charlottesville, Virginia) |
| Trial ID | NCT06292117 on ClinicalTrials.gov |
What this trial studies
This observational study aims to implement a rapid genetic test for CYP2C19 to guide the prescription of dual antiplatelet therapy in patients who have experienced an acute ischemic stroke or transient ischemic attack. The study will evaluate the feasibility and acceptability of using this genetic test in an acute inpatient setting and analyze its impact on prescribing patterns for blood thinners. Patients will undergo rapid genotyping to determine their CYP2C19 status, and results will be integrated into electronic health records to inform clinical decision-making.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who present with symptoms of acute ischemic stroke or transient ischemic attack and are eligible for dual antiplatelet therapy.
Not a fit: Patients who are receiving therapeutic anticoagulation or have contraindications to dual antiplatelet therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective prevention of recurrent strokes by ensuring patients receive the most suitable blood thinner based on their genetic profile.
How similar studies have performed: Other studies have shown success with similar genetic-guided approaches in optimizing antiplatelet therapy, indicating a promising avenue for precision medicine.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men and women at least 18 years of age * Presenting with symptoms of acute ischemic stroke or transient ischemic attack and without contraindications to dual antiplatelet therapy at time of clinical research coordinator screening * Presenting within 24 of symptom onset; or, within 24-96 hours of symptom onset IF planned to receive or already on dual antiplatelet therapy Exclusion Criteria: * Receiving therapeutic anticoagulation or clear indication for initiation of anticoagulation after event (e.g., known atrial fibrillation) * History of allogeneic bone marrow transplant * History of liver transplant * Subject who is unable to consent and does not have a surrogate available to consent on their behalf
Where this trial is running
Charlottesville, Virginia
- University of Virginia — Charlottesville, Virginia, United States (Recruiting)
Study contacts
- Principal investigator: Rachael M Stone, PharmD — University of Virginia
- Study coordinator: Andrew Weko, MPH
- Email: crx3qp@uvahealth.org
- Phone: 434-297-6777
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.